secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K/A
Filed at:   2023-05-05T23:59:59+00:00
Accession:  0001104659-23-056605
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics details CEO Flores' severance and CFO Diem's compensation
------------------------------------------------------------------------------

- Flores receives 12 months base salary severance, COBRA reimbursement, and extended option exercise to 3 years.
- 80,100 unvested shares of restricted stock fully vest after 6-month advisory period.
- CFO Diem's base salary increased to $500,000 with 45% bonus target.
- Diem receives $500,000 RSU grant vesting 50% Nov 2023 and rest by Nov 2024 or performance milestone.
- Separation agreement includes non-disparagement and cooperation clauses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465923056605/0001104659-23-056605-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465923056605/tm2314832d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-056605

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer